Published January, 2011
Tenofovir Associated With Nonreversible Kidney Disease, Daniel M. Keller, Medscape.com (2011)
This research, presented at the American Society of Nephrology Annual Meeting and described in this article, indicates that tenofovir, an antiretroviral drug used for the treatment of HIV, is associated with an increased risk for events related to kidney disease. In a cohort study of 10,841 HIV-positive treatment-naïve veterans (those who have not previously received drug treatment for HIV) from 1997-2007, researchers from University of California at San Francisco School of Medicine found that with each year of exposure to tenofovir, kidney disease outcomes increase, and these risks do not appear to be reversible even after discontinuing use. The average age of the veterans involved in the study was 46 and 2.3% of the cohort was female.
The researchers note that there are several other factors, including age, race, chronic kidney disease, and other co-occurring disorders that are associated with increased risk for such outcomes and that the specific demographics of the cohort suggest that their findings may not generalize to women, nonveterans, or patients who do not receive regular clinical care.
Copyright Information: CHLP encourages the broad use and sharing of resources. Please credit CHLP when using these materials or their content. and do not alter, adapt or present as your work without prior permission from CHLP.
Legal Disclaimer: CHLP makes an effort to ensure legal information is correct and current, but the law is regularly changing, and the accuracy of the information provided cannot be guaranteed. The legal information in a given resource may not be applicable to all situations and is not—and should not be relied upon—as a substitute for legal advice.